PureTech Health’s (PRTC) Buy Rating Reiterated at Peel Hunt

Peel Hunt reaffirmed their buy rating on shares of PureTech Health (LON:PRTC) in a research note published on Tuesday morning, ThisIsMoney.Co.Uk reports.

Separately, Liberum Capital reiterated a buy rating on shares of PureTech Health in a research note on Thursday, April 23rd.

Shares of LON PRTC opened at GBX 252 ($3.31) on Tuesday. The company has a current ratio of 1.21, a quick ratio of 1.18 and a debt-to-equity ratio of 6.04. PureTech Health has a 12 month low of GBX 2.11 ($0.03) and a 12 month high of GBX 339.36 ($4.46). The firm has a market capitalization of $726.24 million and a PE ratio of 1.76. The firm has a fifty day simple moving average of GBX 249.68 and a two-hundred day simple moving average of GBX 271.05.

In other PureTech Health news, insider John LaMattina purchased 700 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was bought at an average cost of GBX 218 ($2.87) per share, for a total transaction of £1,526 ($2,007.37). Over the last quarter, insiders purchased 15,601 shares of company stock valued at $3,845,046.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Recommended Story: Monthly Dividend Stocks Can Provide Solid Income

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit